The Swiss pharma is paying $12 billion for Avidity Biosciences and its three late-stage antibody oligonucleotide conjugates.

Shares in Novartis had fallen nearly 3.5% at the time of writing, as investors digested the third-quarter figures and ...

Novartis shares were sliding on Tuesday morning, after it reported solid third-quarter revenue growth but missed earnings ...

Novartis has started to feel the squeeze from generics to its top-selling drug, heart therapy Entresto. | Novartis has ...

ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS) following switch to Kesimpta after ...

"Multiple sclerosis: three trials to watch" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

Among individuals with MS, the risk of serious infection was higher and the time to the first serious infection was shorter ...

Dr Devon S. Conway reflects on revised MS diagnostic criteria enabling earlier diagnosis and promising pipeline therapies.

Q3 2025 Earnings Call Transcript October 28, 2025 Novartis AG misses on earnings expectations. Reported EPS is $2.25 EPS, ...

Discusses Immunology Portfolio Update and Advances in Autoimmune Therapies October 30, 2025 11:30 AM EDTCompany ...